

WHAT IS CLAIMED IS:

1. A substantially purified polypeptide comprising an amino acid sequence selected from any one of the following:
  - (a) a polypeptide of SEQ ID NO: 6;
  - (b) a polypeptide having one or more conservative amino acid substitutions to the polypeptide of SEQ ID NO: 6; or
  - (c) a mutant or variant of the polypeptide of SEQ ID NO: 6.
2. A vector which encodes for the polypeptide of claim 1.
3. A cell comprising the vector of claim 2.
4. The cell of claim 3, wherein said cell is a prokaryotic or eukaryotic cell.
5. A process of producing a polypeptide of SEQ ID NO: 6, the process comprising:
  - (a) providing the cell of claim 4;
  - (b) culturing said cell under conditions sufficient to express the SEQ ID NO: 6 polypeptide; and
  - (c) recovering said SEQ ID NO: 6 polypeptide,thereby producing said SEQ ID NO: 6 polypeptide.
6. A method of diagnosing a pathological condition associated with aberrant SEQ ID NO: 6 polypeptide expression or activity in a subject, the method comprising:
  - (a) providing a protein sample from said subject;
  - (b) providing a control protein sample;

(c) measuring the amount of SEQ ID NO: 6 polypeptide in said subject sample; and

(d) comparing the amount of SEQ ID NO: 6 polypeptide in said subject protein sample to the amount of SEQ ID NO: 6 polypeptide in said control protein sample,

wherein an alteration in the amount of SEQ ID NO: 6 polypeptide in said subject protein sample relative to the amount of SEQ ID NO: 6 polypeptide in said control protein sample indicates the subject has said pathological condition.

7. The method of claim 6, wherein said SEQ ID NO: 6 polypeptide is detected using an antibody.
8. The method of claim 6, wherein said pathological condition is cancer.
9. A method for treating, preventing or delaying a pathological condition associated with aberrant SEQ ID NO: 6 expression or activity in a subject, the method comprising administering to a subject in which said treatment, prevention or delay is desired the polypeptide of claim 1 in amount sufficient to treat, prevent or delay said pathological condition in said subject.
10. A method for identifying a compound that binds the polypeptide of claim 1, the method comprising:
  - (a) contacting SEQ ID NO: 6 protein with a compound; and
  - (b) determining whether said compound binds SEQ ID NO: 6 protein.
11. The method of claim 10, wherein binding of said compound to SEQ ID NO: 6 is determined by a protein assay.
12. A compound identified by the method of claim 11.

13. A method for identifying a compound that modulates the activity of a SEQ ID NO: 6 protein, the method comprising:
  - (a) contacting SEQ ID NO: 6 protein with a compound;  
and
  - (b) determining whether SEQ ID NO: 6 protein activity has been altered.
14. A compound identified by the method of claim 13.
15. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically-acceptable carrier.